Australian HREC grants clearance for Cullinan Therapeutics’ SLE treatment trial
The Human Research Ethics Committee (HREC) in Australia has granted clearance for Cullinan Therapeutics to commence an international Phase I clinical trial of CLN-978, a CD19×CD3 bispecific T-cell engager, to treat systemic lupus erythematosus (SLE). The …